AngioDynamics, Inc. (ANGO) EPS Estimated At $0.20

March 14, 2018 - By Nellie Frank

 AngioDynamics, Inc. (ANGO) EPS Estimated At $0.20
Investors sentiment decreased to 1.17 in 2017 Q3. Its down 1.32, from 2.49 in 2017Q2. It dived, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Thomson Horstmann & Bryant reported 0.7% stake. California State Teachers Retirement Systems invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Arizona State Retirement Sys holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 18,996 shares. Ls Invest Advsrs Limited Co has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 1,331 shares. New York-based Gamco Invsts Inc Et Al has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Citadel Advisors Ltd Limited Liability Company reported 88,237 shares. First Quadrant Ltd Partnership Ca reported 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Deutsche Commercial Bank Ag holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 34,527 shares. Acadian Asset Mngmt Limited Liability Corp owns 81,460 shares. State Of Alaska Department Of Revenue reported 7,248 shares. Capital Fund holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 10,700 shares. Bnp Paribas Arbitrage, a New York-based fund reported 21,329 shares. State Teachers Retirement System reported 0% stake. Gotham Asset Management Ltd Limited Liability Company holds 49,193 shares or 0.01% of its portfolio. Prudential Fincl Incorporated owns 315,051 shares for 0.01% of their portfolio.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35M giving it 21.24 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 1.22% or $0.21 during the last trading session, reaching $16.99. About 164,660 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 15, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. On Tuesday, April 5 the stock rating was downgraded by Canaccord Genuity to “Hold”. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity on Monday, September 4. The firm earned “Hold” rating on Sunday, October 8 by Canaccord Genuity. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Neutral” rating by Piper Jaffray on Friday, April 8. The company was maintained on Wednesday, May 31 by Canaccord Genuity. The stock has “Hold” rating by KeyBanc Capital Markets on Thursday, September 28. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Hold” rating given on Monday, July 10 by Canaccord Genuity. Canaccord Genuity maintained it with “Hold” rating and $16.5 target in Thursday, January 4 report. The company was maintained on Tuesday, July 18 by Canaccord Genuity. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Mkt Perform” rating given on Tuesday, November 10 by Raymond James.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $624.30 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More notable recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: which released: “AngioDynamics: Stay Away” on January 23, 2018, also with their article: “AngioDynamics (ANGO) Banks on Buyouts, Debt Level High” published on January 24, 2018, published: “AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on …” on December 11, 2017. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) were released by: and their article: “AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March …” published on February 27, 2018 as well as‘s news article titled: “AngioDynamics to Present at the 2017 Morgan Stanley Global Healthcare Conference” with publication date: August 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: